Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation

Journal of Medicinal Chemistry

Volumn 52, Issue 2, 2009, Pages 329-335

  Trunzer, Markus ^a   Faller, Bernard ^a   Zimmerlin, Alfred ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; BEPRIDIL; CARVEDILOL; CHLORPROMAZINE; CIBENZOLINE; CITALOPRAM; CYTOCHROME P450; DRUG METABOLITE; KAEMPFEROL; KETAMINE; MAPROTILINE; MEQUITAZINE; MIDAZOLAM; PEFLOXACIN; PROPRANOLOL; TADALAFIL; TOREMIFENE; TRICHOSTATIN A; TROPISETRON; VENLAFAXINE;

ARTICLE; COMPUTER MODEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG METABOLISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER MICROSOME; METABOLITE PREDICTION; METASITE; PREDICTION; TANDEM MASS SPECTROMETRY; DRUG DESIGN; LIQUID CHROMATOGRAPHY; METABOLISM; PHARMACOKINETICS; STANDARD; STATISTICAL MODEL; VALIDATION STUDY;

CHROMATOGRAPHY, LIQUID; DRUG DESIGN; HUMANS; LIKELIHOOD FUNCTIONS; MICROSOMES, LIVER; PHARMACOKINETICS; TANDEM MASS SPECTROMETRY;

EID: 60549095002     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8008663     Document Type: Article

References (22)

1. Williams, J. A.; Hyland, R.; Jones, B. C.; Smith, D. A.; Hurst, S.; Goosen, T. C.; Peterkin, V.; Koup, J. R.; Ball, S. E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUC(i)/ AUC) ratios. Drug Metab. Dispos. 2004, 32, 1201-1208.
2. Bertz, R. J.; Granneman, G. R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 1997, 32, 210-258.
3. Kennedy, T. Managing the drug discovery/development interface. Drug Discovery Today 1997, 2, 436-444.
4. Kumar, G. N.; Surapaneni, S. Role of drug metabolism in drug discovery and development. Med. Res. Rev. 2001, 21, 397-411.
5. Murray, M.; Petrovic, N. Cytochromes P450: Decision-making tools for personalized therapeutics. Curr. Opin. Mol. Ther. 2006, 8, 480-486.
6. Carlson, T. J.; Fisher, M. B. Recent advances in high throughput screening for ADME properties. Comb. Chem. High Throughput Screening 2008, 11, 258-264.
7. Rendic, S. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab. Rev. 2002, 34, 83-448.
8. Zhang, N. Y.; Fountain, S. T.; Bi, H. G.; Rossi, D. T. Quantification and rapid metabolite identification in drug discovery using API time- of-flight LC/MS. Anal. Chem. 2000, 72, 800-806.
9. Obach, R. S. Prediction of human clearance of 29 drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half- life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 1999, 27, 1350-1359.
10. Castro-Perez, J. M. Current and future trends in the application of HPLC-MS to metabolite-identification studies. Drug Discovery Today 2007, 12, 249-256.
11. Li, A. C.; Alton, D.; Bryant, M. S.; Shou, W. Z. Simultaneously quantifying parent drugs and screening for metabolites in plasma pharmacokinetic samples using selected reaction monitoring information-dependent acquisition on a QTrap instrument. Rapid Commun. Mass Spectrom. 2005, 19, 1943-1950.
12. Shou, W. Z.; Magis, L.; Li, A. C.; Bryant, M. S. A novel approach to perform metabolite screening during the quantitative LC-MS/MS analyses of in vitro metabolic stability samples using a hybrid triple- quadrupole linear ion trap mass spectrometer. J. Mass Spectrom. 2005, 40, 1347-1356.
13. Tiller, P. R.; Romanyshyn, L. A. Liquid chromatography/tandem mass spectrometric quantification with metabolite screening as a strategy to enhance the early drug discovery process. Rapid Commun. Mass Spectrom. 2002, 16, 1225-1231.
14. Madden, J. C.; Cronin, M. T. D. Structure-based methods for the prediction of drug metabolism. Expert Op. Drug Metab. Toxicol. 2006, 2, 545-557.
15. Anari, M. R.; Baillie, T. A. Bridging cheminformatic metabolite prediction and tandem mass spectrometry. Drug Discovery Today 2005, 10, 711-717.
16. Cruciani, G.; Carosati, E.; De Boeck, B.; Ethirajulu, K.; Mackie, C.; Howe, T.; Vianello, R. MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J. Med. Chem. 2005, 48, 6970-6979.
17. Zhou, D. S.; Afzelius, L.; Grimm, S. W.; Andersson, T. B.; Zauhar, R. J.; Zamora, I. Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions. Drug Metab. Dispos. 2006, 34, 976-983.
18. Caron, G.; Ermondi, G.; Testa, B. Predicting the oxidative metabolism of statins: An application of the MetaSite (R) algorithm. Pharm. Res. 2007, 24, 480-501.
19. Carlson, T. J.; Fisher, M. B. Recent advances in high throughput screening for ADME properties. Comb. Chem. High Throughput Screening 2008, 11, 258-264.
20. Drexler, D. M.; Belcastro, J. V.; Dickinson, K. E.; Edinger, K. J.; Hnatyshyn, S. Y.; Josephs, J. L.; Langish, R. A.; McNaney, C. A.; Santone, K. S.; Shipkova, P. A.; Tymiak, A. A.; Zvyaga, T. A.; Sanders, M. An automated high throughput liquid chromatography- mass spectrometry process to assess the metabolic stability of drug candidates. Assay Drug Dev. Technol. 2007, 5, 247-264.
21. Breinholt, V. M.; Offord, E. A.; Brouwer, C.; Nielsen, S. E.; Brosen, K.; Friedberg, T. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem. Toxicol. 2002, 40, 609-616.
22. Nielsen, S. E.; Breinholt, V.; Justesen, U.; Cornett, C.; Dragsted, L. O. In vitro biotransformation of flavonoids by rat liver microsomes. Xenobiotica 1998, 28, 389-401. JM8008663